Phoebe Biosciences

Phoebe Biosciences is a preclinical-stage biotechnology company dedicated to developing next-generation immunotherapies for solid tumors. The company's primary focus is on targeting the B7 family of immune checkpoint proteins, specifically B7-H4 and B7-H3, which are overexpressed in various cancers and contribute to immune evasion. By leveraging its proprietary platform, Phoebe Biosciences aims to create highly specific and potent therapeutic candidates, including monoclonal antibodies, to overcome resistance to current checkpoint inhibitors. The company is currently advancing its lead programs through preclinical development to address significant unmet needs in oncology. Based in San Jose, California, Phoebe Biosciences is led by experts in immunology and antibody engineering.